We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

127 hedge funds and large institutions have $1.06B invested in Alder Biopharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 55 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 24

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

3% more funds holding

Funds holding: 123 → 127 (+4)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

1% less call options, than puts

Call options by funds: $1.15M | Put options by funds: $1.16M

12% less capital invested

Capital invested by funds: $1.21B → $1.06B (-$147M)

Holders
127
Holders Change
+4
Holders Change %
+3.25%
% of All Funds
2.76%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
20
Increased
55
Reduced
24
Closed
13
Calls
$1.15M
Puts
$1.16M
Net Calls
-$10K
Net Calls Change
-$387K

Top Buyers

1
BG
Bellevue Group
Switzerland
+$34.3M
2
Marshall Wace
Marshall Wace
United Kingdom
+$20M
3
BlackRock
BlackRock
New York
+$14.2M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$8.99M
5
Goldman Sachs
Goldman Sachs
New York
+$6.78M

Top Sellers

1
PHS
PFM Health Sciences
California
-$31.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$17.1M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$7.8M
4
SSA
Schonfeld Strategic Advisors
New York
-$2.43M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$1.66M +$78.5K +6,485 +5%
Barclays
52
Barclays
United Kingdom
$1.49M +$1.33M +109,961 +664%
Swiss National Bank
53
Swiss National Bank
Switzerland
$1.33M – – –
California State Teachers Retirement System (CalSTRS)
54
California State Teachers Retirement System (CalSTRS)
California
$1.32M +$272K +22,450 +25%
MOACM
55
Mutual of America Capital Management
New York
$1.3M +$872 +72 +0.1%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$1.27M +$4.32K +357 +0.3%
AllianceBernstein
57
AllianceBernstein
Tennessee
$1.26M +$48.4K +4,000 +4%
Nomura Holdings
58
Nomura Holdings
Japan
$1.12M +$1.15M +95,000 New
Susquehanna International Group
59
Susquehanna International Group
Pennsylvania
$992K +$1.02M +84,270 New
Macquarie Group
60
Macquarie Group
Australia
$883K – – –
New York State Common Retirement Fund
61
New York State Common Retirement Fund
New York
$879K +$243K +20,100 +37%
Stifel Financial
62
Stifel Financial
Missouri
$856K -$299K -24,730 -25%
TRSOTSOK
63
Teachers Retirement System of the State of Kentucky
Kentucky
$799K +$30.3K +2,502 +4%
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$749K -$34K -2,810 -4%
Jacobs Levy Equity Management
65
Jacobs Levy Equity Management
New Jersey
$732K -$283K -23,400 -27%
PPA
66
Parametric Portfolio Associates
Washington
$730K +$5.52K +456 +0.7%
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$730K +$489K +40,400 +167%
CSS
68
Cubist Systematic Strategies
Connecticut
$727K +$207K +17,062 +38%
California Public Employees Retirement System
69
California Public Employees Retirement System
California
$657K +$69K +5,700 +11%
D.E. Shaw & Co
70
D.E. Shaw & Co
New York
$647K +$665K +54,912 New
SSA
71
Schonfeld Strategic Advisors
New York
$622K -$2.43M -200,400 -79%
UBS Group
72
UBS Group
Switzerland
$591K -$868K -71,682 -59%
AIG
73
American International Group
New York
$546K +$112K +9,230 +25%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$542K +$86.1K +7,112 +18%
Allianz Asset Management
75
Allianz Asset Management
Germany
$466K -$29.7K -2,452 -6%
1 2
3
4 5

ALDR Hedge Fund Activity: Q2 2019 in Review

127 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2019, worth a combined $1.06B — down 12% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ALDR positions and 13 closed out — a net gain of 7 holders — while 55 added to existing stakes and 24 trimmed.

The largest buyer was Bellevue Group, adding an estimated $34.3M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $31.5M sold.

  • 127 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2019, up from 123 in Q1 2019.
  • Funds reported $1.06B of Alder Biopharmaceuticals stock for Q2 2019, down 12% quarter-over-quarter.
  • 20 funds opened new Alder Biopharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +7 holders.
  • The largest Alder Biopharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $34.3M added.
  • The largest Alder Biopharmaceuticals seller in Q2 2019 was PFM Health Sciences, an estimated $31.5M sold.

Based on aggregated 13F filings for Q2 2019.